Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Phase 1 Completed 37 enrolled Duke University National Cancer Institute (NCI) · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Imatinib mesylate, vatalanib, and hydroxyurea may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vatalanib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving imatinib mesylate and vatalanib together with hydroxyurea may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate and vatalanib when given together with hydroxyurea in treating patients with recurrent or relapsed malignant glioma.

Timeline

Start: 2005-07
Primary completion: 2009-01
Completion: —

Publications

Results Reardon DA, Egorin MJ, Desjardins A, Vredenburgh JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon JE 2nd, Salvado AJ, Friedman HS. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer. 2009 May 15;115(10):2188-98. doi: 10.1002/cncr.24213.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Hydroxyurea	Other / unclassified	500 mg	Oral
Subject	Imatinib	Small molecule	400 mg	Oral
Subject	Imatinib	Small molecule	500 mg	Oral
Subject	vatalanib	Small molecule	500 mg	Oral
Subject	vatalanib	Small molecule	1000 mg	Oral
Subject	vatalanib	Small molecule	1250 mg	Oral

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Summary

Timeline

Publications

Drugs

Indications